Vanguard Capital Management’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Vanguard Capital Management’s Portfolio SGMO Stock Details SGMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-12,704,408	Closed	-$3.14M	–	4141
2026 Q1	$3.14M	Buy	+12,704,408	New	+$5.06M	﹤0.01%	3221

Other funds holding SGMO

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Simplex Trading Chicago, Illinois $171B AUM 85% 1-Year Est. Return

AIM

Axiom Investment Management New York $150M AUM

FTUS

Flow Traders U.S. New York $2.43B AUM 44.44% 1-Year Est. Return

HIG

Heritage Investment Group Pompano Beach, Florida $744M AUM 20.51% 1-Year Est. Return

Vanguard Capital Management's SGMO Position: Q2 2026 in Review

Vanguard Capital Management sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q2 2026, closing a stake of 12,704,408 shares — an estimated $3.14M sold.

Vanguard Capital Management first reported a position in SGMO in Q1 2026 and held it in 1 quarter. The position peaked at $3.14M in Q1 2026. 6 funds tracked by Wall St. Rank hold SGMO as of Q2 2026.

Vanguard Capital Management reported no remaining SANGAMO THERAPEUTICS INC position as of Q2 2026 after selling out during the quarter.
Vanguard Capital Management sold 12,704,408 SANGAMO THERAPEUTICS INC shares in Q2 2026, an estimated $3.14M.
Vanguard Capital Management first reported a position in SANGAMO THERAPEUTICS INC in Q1 2026 and held it in 1 quarter.
Vanguard Capital Management's SANGAMO THERAPEUTICS INC position peaked at $3.14M in Q1 2026.
6 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.